Calcipotriol/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: A prospective, noninterventional, multicenter study of treatment outcomes and patient satisfaction

An innovative foam formulation for the fixed‐dose combination of calcipotriol and betamethasone dipropionate (Cal/BD) has recently become available for the treatment of psoriasis vulgaris. Observational studies of patients treated with Cal/BD foam in routine practice have been conducted in several W...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2022-11, Vol.49 (11), p.1085-1095
Main Authors: Jo, Seong Jin, Park, Chul‐Jong, Bang, Chul Hwan, Jeong, Ki‐Heon, Shin, Bong Seok, Kim, Dong Hyun, Park, Hai‐Jin, Kim, Byung‐Soo, Song, Hae‐Jun, Lee, Ju‐Hee, Youn, Sang Woong
Format: Article
Language:English
Subjects:
betamethasone dipropionate
calcipotriol drug combination
Clinical outcomes
health‐related quality of life
Immunoglobulin A
Korea
Observational studies
observational study
Patient satisfaction
Patients
Psoriasis
Psoriasis vulgaris
Quality of life
Safety
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An innovative foam formulation for the fixed‐dose combination of calcipotriol and betamethasone dipropionate (Cal/BD) has recently become available for the treatment of psoriasis vulgaris. Observational studies of patients treated with Cal/BD foam in routine practice have been conducted in several Western countries, but there are limited data on outcomes in Asian patients. We performed a prospective, open‐label, noncomparative, noninterventional study to investigate treatment outcomes and satisfaction in adult patients receiving Cal/BD foam for psoriasis vulgaris in dermatological centers and outpatient clinics in Korea. Data were collected at the time of enrollment (Visit 1) and at a routine clinic visit ~4 weeks later (Visit 2). In total, 218 patients were enrolled, of whom 175 were included in the safety analysis set (58.9% male; mean age ± standard deviation 46.7 ± 15.1 years; use of Cal/BD foam at least once daily 74.3%). Of the safety analysis set, 166 patients had at least mild psoriasis (Investigator Global Assessment [IGA] ≥ 2) and were analyzed for treatment outcomes and satisfaction. Of the 166 patients, 71.7% had mild psoriasis (IGA 2) at baseline. The majority (57.8%) achieved an IGA of 0/1 (clear/almost clear) at Visit 2. The Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) showed significant improvements from Visit 1 to Visit 2 (PASI −2.4 ± 3.0, DLQI −4.5 ± 5.2, both P 
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.16519